The Earlham Institute (EI) is a research institute applying advanced genomics and computational approaches to aid our understanding of complex biological systems and their interaction with the environment.
Established in 2009 and located on the Norwich Research Park, EI is strategically funded by the UK’s Biotechnology and Biological Sciences Research Council (BBSRC).
The Earlham Institute (EI) uses expertise in genomics, bioinformatics and molecular biology to answer complex biological questions and improve plant and animal health, and tackle global issues of food security, climate change, conservation and human wellbeing.
EI is home to state-of-the-art laboratories, specialist equipment and facilities enabling genomics and bioinformatics research, including one of the largest supercomputing facilities for life science research in Europe.
Our technology platforms include:
• Genomics and Single-Cell Analysis facility that provides scalable infrastructure for high-throughput DNA/RNA analysis of biological systems.
• BIO Foundry facility that provides services for high-throughput, nanoscale DNA-assembly, low-cost sequence validation of synthetic constructs and microfermentation.
• High-Performance Computing platform that provides access to high-throughput computing clusters and data management support.
• State-of-the-art training facility for bioinformatics and genomics with expert-led courses.
EI has established collaborative projects worldwide. We are involved in collaborative R&D projects with industry through consultancy, contract research, and grant funding.
Established in 2009 and located on the Norwich Research Park, EI is strategically funded by the UK’s Biotechnology and Biological Sciences Research Council (BBSRC).
The Earlham Institute (EI) uses expertise in genomics, bioinformatics and molecular biology to answer complex biological questions and improve plant and animal health, and tackle global issues of food security, climate change, conservation and human wellbeing.
EI is home to state-of-the-art laboratories, specialist equipment and facilities enabling genomics and bioinformatics research, including one of the largest supercomputing facilities for life science research in Europe.
Our technology platforms include:
• Genomics and Single-Cell Analysis facility that provides scalable infrastructure for high-throughput DNA/RNA analysis of biological systems.
• BIO Foundry facility that provides services for high-throughput, nanoscale DNA-assembly, low-cost sequence validation of synthetic constructs and microfermentation.
• High-Performance Computing platform that provides access to high-throughput computing clusters and data management support.
• State-of-the-art training facility for bioinformatics and genomics with expert-led courses.
EI has established collaborative projects worldwide. We are involved in collaborative R&D projects with industry through consultancy, contract research, and grant funding.
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.. EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:. •
EIP is an innovative Intellectual Property law firm advising on all areas of IP. EIP has more than 60 professional staff practising from its four UK offices in Bath, Cardiff, Leeds and London, its US office in Denver and its German office in Dusseldorf. EIP Life is our life sciences and medical devices team which has a wealth of technical knowledge and experience in dealing with the biotechnology and health sectors, for start-ups and major multinationals.
Lilly is developing a growing portfolio of best in class pharmaceutical products by applying the latest research from our own laboratories and from collaborations with eminent scientific organisations worldwide. In 2003 the company's world-wide sales were more than $12 billion. Lilly employs more than 43000 people worlwide and markets medicines in 158 countries. Lilly Research Laboratories (the R&D division of the company) employs more than 8000 people from a wide variety of disciplines. The company has R&D facilities in 9 countries and currently conducts clinical trials in more then 60 countries around the world. . . Lilly's internal research efforts are focused in the following major therapeutic areas: cancer, cardiovascular diseases, endocrinology, neuroscience, gene regulation, bone biology, immunomodulation and Inflammation Compounds in late stage development, and those currently being launched have promise to address the needs of patients with sepsis, cancer, diabetes, depression, osteoporosis, erectile dysfunction, urinary incontinence and attention deficit hyperactivity disorder.. . In pursuit of innovation Lilly seeks to incorporate those cutting edge technologies which support the high quality, rapid identification and investigation of novel compounds.. . The company approach to innovation includes a commitment to the philosophy of research without walls - a stated commitment to partnership and external collaboration. Currently Lilly Research Laboratories has more than 120 active collaborations with external scientists.
Watch our Member Showcase video here https://bit.ly/3HZGpJI
Emberion develops and produces graphene photonics and electronics that will revolutionise infrared photodetectors and thermal sensors in applications ranging from hyperspectral and thermal imaging to night vision and X-ray detection.
Empyrean Therapeutics is focused on developing next generation off-the-shelf cell therapies to enable global and affordable cures for cancer and rare disease. We are building unique technologies, cellular assets and engineering processes which combine to deliver a powerful platform for rapidly manufacturing cellular drugs with novel disease fighting properties. . . Headquartered at the Babraham Research Campus, south of Cambridge, and working with leading clinical partners and academic experts, we are combining world class skills in gene editing with expertise in stem cell programming and precise genetic control to unlock the true potential of designer cellular medicines.
No data available
Immunotherapeutics company targeting a new class of tumour specific antigens
Ernst & Young is also a global leader in professional services with some 114,000 people based in 140 countries. Around the world the firm is committed to pursuing the highest levels of integrity, quality, and professionalism in delivering a broad inventory of services to our clients. Our services fall under three broad headings: Assurance and Advisory Business Services (AABS), Transaction Advisory Services (TAS) and Taxation Services. Our 'account-centric' organisational model recognises that many client issues are best addressed by a number of our service lines working together.. Ernst & Young UK comprises approximately 470 partners and 8000 staff. In 2006 UK fee income increased by 20% to £1.13bn whilst staff numbers excluding partners increased by 8% to 7,902. We provided services to 84 of the FTSE 100 companies and 93% of our clients indicated they were satisfied or very satisfied with our service. For the second year running, we qualified for the Per Cent Standard, meaning that we gave more than 1% of our notional pre-tax profits to charity and we ranked 61st in the Business in the Community's Environment Index.. . COMMITMENT TO BIOTECHNOLOGY. For the past 20 years, Ernst &Young has been a leading professional services firm serving the biotechnology industry, thanks to our extensive global network of experienced professionals and our industry-leading annual publication, Beyond Borders: The Global Biotechnology Report.. Now recognised as the industry bible, Ernst & Young's global biotechnology report, Beyond Borders, provides an overview of the latest developments in the global biotechnology sector. Our report demonstrates that on the cusp of its 30th birthday, the biotech industry is maturing rapidly, with solid financial performance and a substantial track record of bringing new products to market. The contents and themes of this report derive from substantial research by our Global Biotechnology Center, and more importantly, from our leading position serving prominent biotechnology companies around the world.. The life sciences industry is widely acknowledged as one of the leading industries in the future global economy, Ernst & Young has helped shape the global life sciences industry since its inception, advising more of its leading companies than any other professional service firm. We advise one third of life sciences companies globally, have a global network of life sciences specialists in 17 European countries, and boast the UK's largest dedicated life sciences team which our Cambridge office forms part of.. We are reporting accountants to companies in respect of their IPOs on AIM, the London Stock Exchange, and NASDAQ, and are experts in providing tax planning advice for companies seeking IPOs including share option planning.. . CONTACTS:. Julian Jenkins (Audit Partner). 01223 557073. Cathy Taylor (Tax Partner). 01223 557090. Simon Gillings (Transaction Support). 01223 557071